-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 31, Yifan Pharma released an announcement on the progress of the F-627 project, a product under development by its holding subsidiary
,
The announcement shows that EviveBiotech Ltd.
On March 30, 2021, Yiyi Bio, a holding subsidiary of the company, submitted the F-627 biological product license application (BLA) to the US FDA, and received the FDA's acceptance letter on May 27, 2021, agreeing to approve F-627 The target date is March 30, 2022
The specific content of the FDA notification: "When reviewing the submitted F-627 application, we made it clear that before the FDA approves the F-627 marketing application, an on-site inspection of Yiyi Biopharmaceutical (Beijing) Co.
Yifan Pharmaceutical stated that up to now, Yiyi Bio, a subsidiary of the company, has responded to all questions raised by the FDA during the technical review of F-627
